Eletriptan

證據等級: L5

預測適應症: 4 個

Eletriptan: From Migraine to Migraine with Brainstem Aura

One-Sentence Summary

Eletriptan is a second-generation triptan originally approved for the acute treatment of migraine (with or without aura), acting as a selective 5-HT1B/1D receptor agonist to abort migraine attacks. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura (formerly known as basilar-type migraine), with 0 clinical trials and 18 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Acute migraine (with or without aura)
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.99%
Evidence Level	L3
India Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Eletriptan is a selective 5-HT1B/1D receptor agonist (triptan class). Its established mechanism involves two complementary actions: constriction of dilated intracranial blood vessels (via 5-HT1B receptors) and inhibition of neuropeptide release from trigeminal nerve terminals (via 5-HT1D receptors), collectively suppressing neurogenic inflammation and pain signal transmission. This places it squarely within the core pharmacological pathway relevant to all migraine subtypes.

Migraine with brainstem aura is a specific migraine variant where aura symptoms originate from the brainstem (e.g., dysarthria, vertigo, diplopia, ataxia), followed by typical migraine headache. The headache phase shares the same trigeminovascular pathophysiology as common migraine, making the mechanism of eletriptan directly applicable. The key distinction is that basilar/brainstem vasculature (basilar artery territory) is involved—and 5-HT1B receptors are indeed expressed in these vessels, which is both the theoretical basis for efficacy and the primary safety concern (risk of excessive vasoconstriction).

Importantly, the TxGNN prediction is mechanistically coherent rather than speculative: eletriptan is already used clinically to treat migraine with aura (including cases with mild brainstem features), and the distinction between “migraine with aura” and “migraine with brainstem aura” is primarily a diagnostic classification refinement rather than a fundamentally different disease entity. The prediction essentially asks whether established triptan efficacy extends to this formally defined subtype, which is clinically plausible.

Clinical Trial Evidence

Currently no related clinical trials registered for Eletriptan specifically in migraine with brainstem aura.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25600718	2015	Clinical Guideline	Headache	American Headache Society evidence assessment of acute migraine pharmacotherapies; provides updated evidence grading for triptans including eletriptan
11844898	2002	RCT	European Neurology	Double-blind RCT comparing eletriptan 40/80 mg vs. ergotamine/caffeine (Cafergot) vs. placebo; eletriptan 80 mg superior in migraine with or without aura
15469451	2004	Clinical Trial	European Journal of Neurology	Tested eletriptan 80 mg administered during the aura phase; found no significant effect when given during aura, suggesting headache-phase targeting is optimal
12807526	2003	RCT	Cephalalgia	Double-blind, placebo-controlled study (n=446) in patients with prior sumatriptan intolerance; eletriptan demonstrated efficacy in migraine with and without aura
11687056	2001	Systematic Review	Cochrane Database	Cochrane systematic review of eletriptan for acute migraine; comprehensive evidence synthesis supporting efficacy
17636718	2007	Cochrane Review (Withdrawn)	Cochrane Database	Updated Cochrane review, subsequently withdrawn; cited for historical context of evidence base
17501848	2007	Clinical Research	Headache	Multidimensional assessment of functional impairment and work productivity outcomes with eletriptan treatment for acute migraine
21028917	2010	Systematic Review	Paediatric Drugs	Review of triptan use in pediatric migraine; includes eletriptan data across migraine with and without aura subtypes
12498013	2002	Drug Review	Curr Opin Investig Drugs	Pfizer drug profile; describes eletriptan’s 6-fold greater 5-HT1D affinity over sumatriptan and 3-fold greater 5-HT1B affinity, supporting mechanism relevance
25155004	2014	Case Report	Rev Port Cardiol	Case report of myocardial infarction after eletriptan in a patient with non-obstructive CAD and migraine with visual aura — key safety signal for vascular risk population

India Market Information

Eletriptan is currently not registered or marketed in India. No authorisation records are available.

For reference: Eletriptan (brand name Relpax®, Pfizer) is approved and available in the United States, European Union, Japan, and other markets for acute migraine treatment. India market entry would require a new drug application to CDSCO.

Safety Considerations

Drug Interactions (94 interactions on record; key interactions listed below):

Severity	Interacting Drug	Clinical Relevance
Major	Lorcaserin	Serotonin syndrome risk (dual serotonergic activity)
Major	Clarithromycin	CYP3A4 inhibition significantly increases eletriptan exposure
Major	Dolasetron	Additive serotonergic effect; risk of serotonin syndrome
Major	Ondansetron	Additive serotonergic effect; risk of serotonin syndrome
Major	Palonosetron	Additive serotonergic effect; risk of serotonin syndrome
Major	Granisetron	Additive serotonergic effect; risk of serotonin syndrome
Major	Fenfluramine	Major serotonergic interaction risk
Major	Dexfenfluramine	Major serotonergic interaction risk
Major	Sibutramine	Serotonin syndrome risk
Moderate	Aprepitant	CYP3A4 inhibition may increase eletriptan levels
Moderate	Morphine	Moderate interaction; monitor closely
Moderate	Cimetidine	CYP3A4 inhibition; may increase exposure
Moderate	Clotrimazole	CYP3A4 inhibition
Moderate	Miconazole	CYP3A4 inhibition

Note on brainstem aura-specific safety concern: Eletriptan carries a class-level caution for basilar/hemiplegic migraine due to theoretical risk of basilar artery vasoconstriction. This is the primary safety guardrail for the predicted indication and requires specific clinical risk assessment.

For complete warnings and contraindications, refer to the Relpax® (eletriptan) prescribing information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction is mechanistically sound — eletriptan’s 5-HT1B/1D mechanism directly targets the trigeminovascular pathway central to migraine with brainstem aura, and the substantial evidence base for eletriptan in general migraine (including migraine with aura) provides strong mechanistic bridging evidence. However, no clinical trial data specifically in migraine with brainstem aura exists, and the vasoconstrictive risk in basilar territory is a class-level safety concern that has historically led to cautionary labelling.

To proceed, the following is needed:

Regulatory-grade MOA documentation: Retrieve full DrugBank/prescribing information to formally document 5-HT1B/1D mechanism and contraindication language
India CDSCO filing strategy: Eletriptan is not marketed in India; a new drug application or import licence pathway needs to be assessed
Targeted literature review for basilar/brainstem migraine subtypes: Search specifically for triptan use in brainstem aura populations to quantify the vasoconstriction risk-benefit balance
Safety protocol for vascular risk patients: Given the major DDI signals with CYP3A4 inhibitors (clarithromycin) and serotonergic agents (5-HT3 antagonists), a prescribing checklist is recommended
TFDA/international prescribing information review: Download and parse official package insert PDFs to complete the blocking data gap (DG001) before any S1 safety evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.